Indirect treatment comparison and costminimization analysis of riociguat versus selexipag in patients with pulmonary arterial hypertension
Expert review of pharmacoeconomics & outcomes research（2022）
Abstract
Switching to riociguat represents the cost-saving therapy for PAH patients who were inadequately compensated with the PDE5i+ERA therapy. Consequently, riociguat has been introduced to the list of reimbursed medicines in Czechia from October 2021. Based on two global trials, we prepared the first indirect treatment comparison followed with CMA of these therapies that may improve future decision-making for PAH indications.
MoreTranslated text
Key words
Bucher indirect comparison,cost-minimization analysis,pulmonary arterial hypertension,riociguat,selexipag,systematic review
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined